🟢 Chimeric Therapeutics is trading 11.11% up today after stopping CHM-2101 dosing over dose-limiting toxicity

Chimeric Therapeutics is trading 11.11% up at A$0.02 after stopping CHM-2101 Phase 1 enrolment and dosing on August 19, 2026, following dose-limiting toxicity in a second Dose Level 3 patient.

• The company will not progress CHM-2101 in its current autologous CAR-T form.
• It is exploring an in-vivo CDH17 therapy.
• Anti-tumour activity across all 14 treated patients may be supporting the rebound.